The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
CD56bright NK cells exhibit potent antitumor responses following IL-15 priming
Open accessAbstract
NK cells, lymphocytes of the innate immune system, are important for defense against infectious pathogens and cancer. Classically, the CD56dim NK cell subset is thought to mediate antitumor responses, whereas the CD56bright subset is involved in immunomodulation. Here, we challenge this paradigm by demonstrating that brief priming with IL-15 markedly enhanced the antitumor response of CD56bright NK cells. Priming improved multiple CD56bright cell functions: degranulation, cytotoxicity, and cytokine production. Primed CD56bright cells from leukemia patients demonstrated enhanced responses to autologous blasts in vitro, and primed CD56bright cells controlled leukemia cells in vivo in a murine xenograft model. Primed CD56bright cells from multiple myeloma (MM) patients displayed superior responses to autologous myeloma targets, and furthermore, CD56bright NK cells from MM patients primed with the IL-15 receptor agonist ALT-803 in vivo displayed enhanced ex vivo functional responses to MM targets. Effector mechanisms contributing to IL-15-based priming included improved cytotoxic protein expression, target cell conjugation, and LFA-1-, CD2-, and NKG2D-dependent activation of NK cells. Finally, IL-15 robustly stimulated the PI3K/Akt/mTOR and MEK/ERK pathways in CD56bright compared with CD56dim NK cells, and blockade of these pathways attenuated antitumor responses. These findings identify CD56bright NK cells as potent antitumor effectors that warrant further investigation as a cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380
The biology of human natural killer-cell subsets
Cooper, M. A., Fehniger, T. A., & Caligiuri, M. A. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)02060-9 · Cited by 2,975
Self-citationLanier, L. L. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115526 · Cited by 2,769
Caligiuri, M. A. (2008) · Blood · doi:10.1182/blood-2007-09-077438 · Cited by 1,905
Miller, J. S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D., Le, C., Defor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,903
Self-citationThe role of interleukin-2 during homeostasis and activation of the immune system
Boyman, O., & Sprent, J. (2012) · Nature Reviews Immunology · doi:10.1038/nri3156 · Cited by 1,657
Amir, E.-A. D., Davis, K. L., Tadmor, M. D., Simonds, E. F., Levine, J. H., Bendall, S. C., Shenfeld, D. K., Krishnaswamy, S., Nolan, G. P., & Pe'er, D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2594 · Cited by 1,550
Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset
Cooper, M. A., Fehniger, T. A., Turner, S. C., Chen, K. S., Ghaheri, B. A., Ghayur, T., Carson, W. E., & Caligiuri, M. A. (2001) · Blood · doi:10.1182/blood.v97.10.3146 · Cited by 1,449
Self-citationControlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition
Long, E. O., Sik Kim, H., Liu, D., Peterson, M. E., & Rajagopalan, S. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075005 · Cited by 1,217
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
Koreth, J., Matsuoka, K.-I., Kim, H. T., McDonough, S. M., Bindra, B., Alyea, E. P., Armand, P., Cutler, C., Ho, V. T., Treister, N. S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108188 · Cited by 1,119
Interleukin 15: biology and relevance to human disease
Fehniger, T. A., & Caligiuri, M. A. (2001) · Blood · doi:10.1182/blood.v97.1.14 · Cited by 976
Self-citationRomee, R., Rosario, M., Berrien-Elliott, M. M., Wagner, J. A., Jewell, B. A., Schappe, T., Leong, J. W., Abdel-Latif, S., Schneider, S. E., Willey, S., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2341 · Cited by 942
Self-citationDendritic Cells Prime Natural Killer Cells by trans-Presenting Interleukin 15
Lucas, M., Schachterle, W., Oberle, K., Aichele, P., & Diefenbach, A. (2007) · Immunity · doi:10.1016/j.immuni.2007.03.006 · Cited by 887
Fehniger, T. A., Cooper, M. A., Nuovo, G. J., Cella, M., Facchetti, F., Colonna, M., & Caligiuri, M. A. (2003) · Blood · doi:10.1182/blood-2002-09-2876 · Cited by 857
Self-citationCytokine-induced memory-like natural killer cells
Cooper, M. A., Elliott, J. M., Keyel, P. A., Yang, L., Carrero, J. A., & Yokoyama, W. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813192106 · Cited by 831
Conlon, K. C., Lugli, E., Welles, H. C., Rosenberg, S. A., Fojo, A. T., Morris, J. C., Fleisher, T. A., Dubois, S. P., Perera, L. P., Stewart, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3329 · Cited by 711
Cytokine activation induces human memory-like NK cells
Romee, R., Schneider, S. E., Leong, J. W., Chase, J. M., Keppel, C. R., Sullivan, R. P., Cooper, M. A., & Fehniger, T. A. (2012) · Blood · doi:10.1182/blood-2012-04-419283 · Cited by 684
Self-citationFehniger, T. A., Shah, M. H., Turner, M. J., VanDeusen, J. B., Whitman, S. P., Cooper, M. A., Suzuki, K., Wechser, M., Goodsaid, F., & Caligiuri, M. A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.8.4511 · Cited by 652
Self-citationRubnitz, J. E., Inaba, H., Ribeiro, R. C., Pounds, S., Rooney, B., Bell, T., Pui, C.-H., & Leung, W. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.4590 · Cited by 649
Foley, B., Cooley, S., Verneris, M. R., Pitt, M., Curtsinger, J., Luo, X., Lopez-Vergès, S., Lanier, L. L., Weisdorf, D., & Miller, J. S. (2012) · Blood · doi:10.1182/blood-2011-10-386995 · Cited by 630
Marçais, A., Cherfils-Vicini, J., Viant, C., Degouve, S., Viel, S., Fenis, A., Rabilloud, J., Mayol, K., Tavares, A., Bienvenu, J., et al. (2014) · Nature Immunology · doi:10.1038/ni.2936 · Cited by 614
Formation and function of the lytic NK-cell immunological synapse
Orange, J. S. (2008) · Nature Reviews Immunology · doi:10.1038/nri2381 · Cited by 610
Cooley, S., Weisdorf, D. J., Guethlein, L. A., Klein, J. P., Wang, T., Le, C. T., Marsh, S. G. E., Geraghty, D., Spellman, S., Haagenson, M. D., et al. (2010) · Blood · doi:10.1182/blood-2010-05-283051 · Cited by 591
Ferlazzo, G., Thomas, D., Lin, S.-L., Goodman, K., Morandi, B., Muller, W. A., Moretta, A., & Münz, C. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.3.1455 · Cited by 589
Ferlazzo, G., Pack, M., Thomas, D., Paludan, C., Schmid, D., Strowig, T., Bougras, G., Muller, W. A., Moretta, L., & Münz, C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407522101 · Cited by 583
Prospects for the use of NK cells in immunotherapy of human cancer
Ljunggren, H.-G., & Malmberg, K.-J. (2007) · Nature Reviews Immunology · doi:10.1038/nri2073 · Cited by 543
Self-citationThe Ins and Outs of Leukocyte Integrin Signaling
Abram, C. L., & Lowell, C. A. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132554 · Cited by 534
Human natural killer cell development
Freud, A. G., & Caligiuri, M. A. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00451.x · Cited by 497
CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells
Jacobs, R., Hintzen, G., Kemper, A., Beul, K., Kempf, S., Behrens, G., Sykora, K.-W., & Schmidt, R. E. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(2001010)31:10<3121::aid-immu3121>3.0.co;2-4 · Cited by 475
Developmental pathways that generate natural-killer-cell diversity in mice and humans
Huntington, N. D., Vosshenrich, C. A. J., & Di Santo, J. P. (2007) · Nature Reviews Immunology · doi:10.1038/nri2154 · Cited by 461
Fehniger, T. A., Cai, S. F., Cao, X., Bredemeyer, A. J., Presti, R. M., French, A. R., & Ley, T. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.04.010 · Cited by 451
Self-citationCooley, S., Trachtenberg, E., Bergemann, T. L., Saeteurn, K., Klein, J., Le, C. T., Marsh, S. G. E., Guethlein, L. A., Parham, P., Miller, J. S., et al. (2009) · Blood · doi:10.1182/blood-2008-07-171926 · Cited by 434
HLA-C–Dependent Prevention of Leukemia Relapse by Donor Activating KIR2DS1
Venstrom, J. M., Pittari, G., Gooley, T. A., Chewning, J. H., Spellman, S., Haagenson, M., Gallagher, M. M., Malkki, M., Petersdorf, E., Dupont, B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200503 · Cited by 429
Sustained effector function of IL-12/15/18–preactivated NK cells against established tumors
Ni, J., Miller, M., Stojanovic, A., Garbi, N., & Cerwenka, A. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120944 · Cited by 419
IL-15/IL-15 receptor biology: A guided tour through an expanding universe
BUDAGIAN, V, BULANOVA, E., PAUS, R., & BULFONEPAUS, S. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2006.05.001 · Cited by 385
Robertson, M. J., Soiffer, R. J., Wolf, S. F., Manley, T. J., Donahue, C., Young, D., Herrmann, S. H., & Ritz, J. (1992) · The Journal of experimental medicine · doi:10.1084/jem.175.3.779 · Cited by 354
Metabolic Reprogramming Supports IFN-γ Production by CD56bright NK Cells
Keating, S. E., Zaiatz-Bittencourt, V., Loftus, R. M., Keane, C., Brennan, K., Finlay, D. K., & Gardiner, C. M. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501783 · Cited by 325
LFA-1 Contributes an Early Signal for NK Cell Cytotoxicity
Barber, D. F., Faure, M., & Long, E. O. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.3653 · Cited by 321
Regulated expression of Mg2+ binding epitope on leukocyte integrin alpha subunits.
Dransfield, I., & Hogg, N. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb08552.x · Cited by 318
Functional Significance of CD57 Expression on Human NK Cells and Relevance to Disease
Nielsen, C. M., White, M. J., Goodier, M. R., & Riley, E. M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00422 · Cited by 282
Interleukin-2 and interleukin-15: immunotherapy for cancer
Fehniger, T. A., Cooper, M. A., & Caligiuri, M. A. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00021-1 · Cited by 280
Self-citationNguyen, S., Dhedin, N., Vernant, J.-P., Kuentz, M., Jijakli, A. A., Rouas-Freiss, N., Carosella, E. D., Boudifa, A., Debré, P., & Vieillard, V. (2005) · Blood · doi:10.1182/blood-2004-10-4113 · Cited by 250
Molecular Pathways: Interleukin-15 Signaling in Health and in Cancer
Mishra, A., Sullivan, L., & Caligiuri, M. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3603 · Cited by 244
Rhode, P. R., Egan, J. O., Xu, W., Hong, H., Webb, G. M., Chen, X., Liu, B., Zhu, X., Wen, J., You, L., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0093-t · Cited by 225
Self-citationCell biological steps and checkpoints in accessing NK cell cytotoxicity
Mace, E. M., Dongre, P., Hsu, H., Sinha, P., James, A. M., Mann, S. S., Forbes, L. R., Watkin, L. B., & Orange, J. S. (2014) · Immunology & Cell Biology · doi:10.1038/icb.2013.96 · Cited by 218
The Critical Role of IL-15–PI3K–mTOR Pathway in Natural Killer Cell Effector Functions
Nandagopal, N., Ali, A. K., Komal, A. K., & Lee, S.-H. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00187 · Cited by 196
Nielsen, N., Ødum, N., Ursø, B., Lanier, L. L., & Spee, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031959 · Cited by 172
Mao, Y., van Hoef, V., Zhang, X., Wennerberg, E., Lorent, J., Witt, K., Masvidal, L., Liang, S., Murray, S., Larsson, O., et al. (2016) · Blood · doi:10.1182/blood-2016-02-698027 · Cited by 172
Chapter 2 Natural Killer Cell Tolerance
Jonsson, A. H., & Yokoyama, W. M. (2009) · Advances in immunology · doi:10.1016/s0065-2776(08)01002-x · Cited by 168
Utilizing Cytokines to Function-Enable Human NK Cells for the Immunotherapy of Cancer
Romee, R., Leong, J. W., & Fehniger, T. A. (2014) · Scientifica · doi:10.1155/2014/205796 · Cited by 164
Self-citationNatural killer cells: walking three paths down memory lane
Min‐Oo, G., Kamimura, Y., Hendricks, D. W., Nabekura, T., & Lanier, L. L. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.02.005 · Cited by 159
Dulphy, N., Haas, P., Busson, M., Belhadj, S., de Latour, R. P., Robin, M., Carmagnat, M., Loiseau, P., Tamouza, R., Scieux, C., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.2227 · Cited by 156
Novel Human Interleukin-15 Agonists
Zhu, X., Marcus, W. D., Xu, W. V., Lee, H.-I., Han, K., Egan, J. O., Yovandich, J. L., Rhode, P. R., & Wong, H. C. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901244 · Cited by 155
Self-citationRosario, M., Liu, B., Kong, L., Collins, L. I., Schneider, S. E., Chen, X., Han, K., Jeng, E. K., Rhode, P. R., Leong, J. W., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1419 · Cited by 147
Self-citationTonsilar NK Cells Restrict B Cell Transformation by the Epstein-Barr Virus via IFN-γ
Strowig, T., Brilot, F., Arrey, F., Bougras-Cartron, G., Thomas, D. A., Müller, W. A., & Münz, C. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.0040027 · Cited by 138
Vidal, S. M., Khakoo, S. I., & Biron, C. A. (2011) · Current Opinion in Virology · doi:10.1016/j.coviro.2011.10.017 · Cited by 136
Yu, J.-L., Venstrom, J., Liu, X.-R., Pring, J., Hasan, R. S., O'Reilly, R., & Hsu, K. C. (2009) · Blood · doi:10.1182/blood-2008-09-177055 · Cited by 128
CALLEA, M., Albiges, L. K., Gupta, M., Cheng, S., Genega, E. M., Fay, A. P., Song, J., Carvo, I., Bhatt, R. S., Atkins, M. B., et al. (2015) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · doi:10.1158/2326-6066 · Cited by 125
TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors
Plasilova, M. L., Živný, J., Jelínek, J., Neuwirtová, R., Čermák, J., Nečas, E., Anděra, L., & Stopka, T. (2002) · Leukemia · doi:10.1038/sj.leu.2402338 · Cited by 112
Urlaub, D., Höfer, K., Müller, M., & Watzl, C. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601004 · Cited by 110
Monocytes control natural killer cell differentiation to effector phenotypes
Soderquest, K., Powell, N., Luci, C., van Rooijen, N., Hidalgo, A., Geissmann, F., Walzer, T., Lord, G. M., & Martin‐Fontecha, A. (2011) · Blood · doi:10.1182/blood-2010-10-312264 · Cited by 107
Messaoudene, M., Fregni, G., Fourmentraux-Neves, E., Chanal, J., Maubec, E., Mazouz-Dorval, S., Couturaud, B., Girod, A., Sastre‐Garau, X., Albert, S., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1303 · Cited by 106
Takahashi, E., Kuranaga, N., Satoh, K., et al. (2007) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2006.01883.x · Cited by 103
Björklund, A., Schaffer, M., Fauriat, C., Ringdén, O., Remberger, M., Hammarstedt, C., Barrett, A., Ljungman, P., Ljunggren, H., & Malmberg, K. (2010) · Blood · doi:10.1182/blood-2009-07-229740 · Cited by 93
Self-citationLincz, L. F., Yeh, T.-X., & Spencer, A. G. (2001) · Leukemia · doi:10.1038/sj.leu.2402251 · Cited by 88
Trotta, R., Parihar, R., Yu, J., Becknell, B., Allard, J., Wen, J., Ding, W., Mao, H., Tridandapani, S., Carson, W. E., et al. (2004) · Blood · doi:10.1182/blood-2004-10-4072 · Cited by 81
Dubois, S. P., Conlon, K. C., Müller, J. R., Hsu-Albert, J., Beltran, N., Bryant, B. R., & Waldmann, T. A. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0279 · Cited by 81
Interleukin-15 in the treatment of cancer
Waldmann, T. A. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.973856 · Cited by 78
Wennerberg, E., Sarhan, D., Carlsten, M., Kaminskyy, V. O., D’Arcy, P., Zhivotovsky, B., Childs, R. W., & Lundqvist, A. (2013) · International Journal of Cancer · doi:10.1002/ijc.28163 · Cited by 65
Anguille, S., Acker, H. H. V., den Bergh, J. V., Willemen, Y., Goossens, H., Tendeloo, V. F. V., Smits, E., Berneman, Z. N., & Lion, E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123340 · Cited by 62
Perez, O. D., Mitchell, D. J., Jager, G. C., & Nolan, G. P. (2004) · Blood · doi:10.1182/blood-2003-08-2652 · Cited by 59
Biology and clinical effects of natural killer cells in allogeneic transplantation
Benjamin, J. E., Gill, S. I., & Negrin, R. S. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328335a559 · Cited by 52
Improving natural killer cell cancer immunotherapy
Berrien-Elliott, M. M., Romee, R., & Fehniger, T. A. (2015) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000243 · Cited by 51
Self-citationActivating Signals Dominate Inhibitory Signals in CD137L/IL-15 Activated Natural Killer Cells
Zhang, H., Cui, Y., Voong, N., Sabatino, M., Stroncek, D. F., Morisot, S., Civin, C. I., Wayne, A. S., Levine, B. L., & Mackall, C. L. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31820d2a21 · Cited by 49
PTEN Is a Negative Regulator of NK Cell Cytolytic Function
Briercheck, E. L., Trotta, R., Chen, L., Hartlage, A. S., Cole, J. P., Cole, T. D., Mao, C., Banerjee, P. P., Hsu, H., Mace, E. M., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401224 · Cited by 47
Use of natural killer cells as immunotherapy for leukaemia
Grzywacz, B. J., Miller, J. S., & Verneris, M. R. (2008) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2008.07.008 · Cited by 37
Activated monocytes augment TRAIL ‐mediated cytotoxicity by human NK cells through release of IFN ‐γ
Sarhan, D., D’Arcy, P., Wennerberg, E., et al. (2012) · European Journal of Immunology · doi:10.1002/eji.201242735 · Cited by 28
Cited by
Exploring the NK cell platform for cancer immunotherapy
Myers, J. A., & Miller, J. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0426-7 · Cited by 1,276
Natural killer cells and other innate lymphoid cells in cancer
Chiossone, L., Dumas, P.-Y., Vienne, M., & Vivier, E. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0061-z · Cited by 1,007
Natural killer cells in cancer biology and therapy
Wu, S.-Y., Fu, T., Jiang, Y.-Z., & Shao, Z.-M. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01238-x · Cited by 863
“cytokines such as IFN-γ, TNF-β and GM-CSF [23].”
BackgroundInfluentialComparative Molecular Analysis of Gastrointestinal Adenocarcinomas
Liu, Y., Sethi, N. S., Hinoue, T., Schneider, B. G., Cherniack, A. D., Sanchez-Vega, F., Seoane, J. A., Farshidfar, F., Bowlby, R., Islam, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.010 · Cited by 615
Roles of natural killer cells in immunity to cancer, and applications to immunotherapy
Wolf, N. K., Kissiov, D. U., & Raulet, D. H. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00732-1 · Cited by 577
Metadata
- Authors
- Wagner, J. A., Rosario, M., Romee, R., Berrien-Elliott, M. M., Schneider, S. E., Leong, J. W., Sullivan, R. P., Jewell, B. A., Becker-Hapak, M., Schappe, T., Abdel-Latif, S., Ireland, A. R., Jaishankar, D., King, J. A., Vij, R., Clement, D., Goodridge, J., Malmberg, K.-J., Wong, H. C., & Fehniger, T. A.
- Venue
- Journal of Clinical Investigation
- Published
- 2017-10-03
- Volume
- 127
- Issue
- 11
- Pages
- 4042-4058
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2763346562
- Cited by
- 297
- References
- 77
- FWCI
- 9.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.